PharosAI is a partnership between King’s College London, Queen Mary University of London, and two innovative NHS Trusts, Guy’s and St Thomas, and Barts Health. PharosAI offers a unique cancer AI product development ecosystem for drug discovery and clinical applications, democratising access to data, AI models, technologies, and capabilities
PharosAI is an initiative funded as part of the Research Venture Catalyst Programme run by the Department for Science, Innovation and Technology (DSIT) to create a platform for AI researchers and companies to access a broad spectrum of cancer-related datasets and AI models. To do this, the project proposes to create a ‘data refinery’ sourced from more than 50,000 patient samples from King’s Health Partners Cancer Biobank and the Breast Cancer Now Tissue Bank, over 28 million data points for AI model training.
Anita Grigoriadas, Professor of Molecular and Digital Pathology, and CEO for PharosAI, said:
“AI holds promise in developing new treatments for the 187,000 people who die of cancer every year in the UK. However, AI raises concerns around data governance, transparency, bias, and equity. New data governance models are needed to radically accelerate cancer AI research. Our membership of the UK Health Data Research Alliance is a critical first step in achieving this goal.”
Website: https://www.pharosai.co.uk/ LinkedIn: PharosAI
